Clinicians, patients and scientists, alike, have been battling cancer for over several decades; however, patient outcomes have not significantly improved over the years with conventional therapies. In recent years, this has caused researchers to look for a change in the status quo, and, the awareness of the human immune system, which has an intrinsic mechanism to control microbial pathogens and dysfunctional self-tissues, has triggered scientists to look for new modes of cancer therapy. Cancer Immunotherapy has become a major research field as a result of these efforts, gaining some recognition for notable breakthroughs in cancer patient prognosis. Frontiers in Cancer Immunology collectively presents the methods which have been studied and used in cancer immunotherapy based on the different components of human immune system. The series will give clinicians and immunologists a roadmap of current trends in all branches of cancer immunology. This volume lists the major immune system components (such as T cells and NK cells and associated antigens/antibodies) which have been demonstrated to limit the growth of or kill tumor cells. Relevant applications in cancer therapy are also included in addition to a general introduction to engineered as well as targeted cancer immunotherapies (cancer vaccines).

Over the past decades, systems biology approaches have been applied in different areas of life science research including oncology. Researchers now understand the hallmarks of cancer cells such as abnormal cell growth, inflammation, dysregulated metabolic pathways and drug resistance properties at a molecular level. Systems biology approaches have enabled researchers to investigate cancer immunology by identifying cancer related biomarkers on immune cells, and to study the effect of different therapies in tissue cultures and mouse models. Systems Biology in Cancer Immunotherapy explains the scope of systems biology in understanding the immune response to neoplasms. The book introduces readers to the concepts crucial to cancer immunology before delving into the applied systems biology topics such as the metabolic pathways in cancer cells, the biomolecular roles of signal transduction molecules and their respective biochemical pathways ad cancer immunotherapy. A brief conclusion at the end also provides some information from a clinical and commercial perspective on cancer immunotherapy. This volume is intended as an introductory reference for life science and medical students, researchers and academics interested in the application of systems biology to the immune system in oncology research and chemotherapy practice.

Frontiers in Clinical Drug Research - Anti-Cancer Agents should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field. The chapters in this volume have been written by leading experts from the field. The contents of this book include new approaches to cancer therapy, treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor-tyrosine kinase inhibitors, targeting key signaling pathways in pediatric brain tumors, current status of cladribine in lymphoid and myeloid malignancies, natural anti-cancer products and the mechanisms of telomere and telomerase regulation in hematologic malignancies. The eBook series is essential to all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the field. The readers will find these reviews valuable and will certainly trigger further research in the pharmaceutical development of anti-cancer agents.

Frontiers in Clinical Drug Research - Anti-Cancer Agents should prove to be a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critical information for developing clinical trials and devising research plans in the field. The chapters featured in each volume are written by leading experts in oncology and clinical pharmacology. The eBook series is essential reading for all scientists involved in clinical drug research who wish to keep abreast of rapid and important developments in the development of anti-cancer agents. The contents of this volume include reviews on dendrimers for anti-cancer drug delivery, treatment methods for advanced cutaneous squamous cell carcinoma, targeting heat shock proteins for cancer treatment, Bayesian systems for optimizing treatment protocols in oncology and much more.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is an eBook series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The third volume of the eBook series begins with a detailed review of the molecular biology of inhibitors that target EGF-family receptors. This review is divided into two parts that covers extracellular and intracellular molecules. Other reviews cover targeted therapies for cancers such as melanoma, follicular lymphoma and topics such as cancer immunotherapy, apoptosis targeting and the Warburg Effect.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The fourth volume of the book brings forth reviews on biomarkers and new drugs used for treating gastrointestinal cancer and breast cancer. The volume also covers the topics of adjuvant therapy, cancer nanodrugs and the role of adiponectin and dicycloplatin in cancer therapy.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology researchers. The fifth volume of the book features reviews on biochemical inhibitors (second-generation protein kinase Inhibitors, histone deacetylase inhibitors, immune checkpoint inhibitors, EGFR Tyrosine Kinase inhibitors, non-coding RNAs), apoptosis, and physical exercise therapy for cancer patients undergoing chemotherapy. The treatment strategies in this volume cover cancers such as acute myeloid leukemia, gastrointestinal cancer, breast cancer and lung cancer.

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The sixth volume of the book features reviews on these topics: · Immunomodulating Agents in The Treatment of Acute Myeloid Leukemia · Potential Natural Products for Prostate Cancer Management · Inhibition of Key Protein-Protein Interactions by Small Molecules for Cancer Drug Design · Efficacy of Hepatic Arterial Infusion Chemotherapy (HAIC) For Advanced Hepatocellular Carcinoma · Targeting Cancer Stem Cells: Implications in Health and Disease

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The seventh volume of the book features reviews on these topics: </P> · Essential oils and monoterpenes as potential anti-cancer agents </P> · Drug delivery systems and emerging immunotherapeutic strategies for the treatment of glioblastoma </P> · CTDNA in solid tumors </P> · Cholesterol treatments (including Pitavastatin) and their potential in cancer treatment

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The eighth volume of the book features reviews on these topics: - Key data management elements in clinical trials for oncological therapeutics - Prospects for therapeutic targeting of microRNAs in brain tumors - Breast cancer vaccines: current status and future approach - Desmocollin-3 and cancer - MDM2-p53 antagonists under clinical evaluation: a promising cancer targeted therapy for cancer patients harbouring wild-type tp53 - Towards targeted therapy: anticancer agents targeting cell organelle mitochondria - Anticancer therapeutic strategies in gliomas: chemotherapy, immunotherapy, and molecularly targeted therapy in adults